ERCC1 and ovarian carcinoma: Cisplatin-resistant TSCC is known to exhibit increased expression of excision repair cross complementation group 1 (ERCC1), a key component of the NER pathway, and previous studies have shown that silencing ERCC1 reverses resistance to cisplatin in gastric and ovarian cancers.